相关实验视频

Updated: Jul 9, 2025

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

对BRCA1,BRCA2和非BRCA乳腺癌的预后进行比较

Pedro Antunes Meireles¹, Sofia Fragoso², Teresa Duarte²

¹Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.

|December 9, 2023

概括

在BRCA1/2基因中的生殖系致病变体 (PV) 会增加乳腺癌 (BC) 复发和死亡风险. 降低风险的手术显著改善了患者的结果,降低了葡萄牙人口中复发和死亡率.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
流行病学流行病学

背景情况:

在BRCA1和BRCA2基因中的生殖系致病变体 (PV) 与遗传性乳腺/卵巢癌综合征有关,占家族性乳腺癌 (BC) 的20%.
之前对BRCA1/2和BC结局的研究显示了相互矛盾的结果,通常与BRCA1BC患者的比例更高.
在葡萄牙,BRCA2BC比BRCA1BC更为普遍,需要对特定人群进行结果分析.

研究的目的:

为了比较BRCA1和BRCA2突变的BC患者和没有生殖系PV (BRCA-wt) 的对照组之间的临床病理学特征和预后.
调查BRCA突变BC患者风险降低手术的频率和影响.

主要方法:

对被诊断为BRCA1/2 PV的BC患者的前性随访.
根据年龄,十年和诊断阶段,建立了一个没有生殖线PV (BRCA-wt) 的BC患者匹配的对照组.
在三组中比较整体存活率 (OS) 和无侵袭性疾病存活率 (iDFS),并分析BRCA队列中降低风险的手术结果.

主要成果:

与BRCA突变患者相比,BRCA-wt患者出现复发和OS的时间明显较长 (平均随访时间:113.0个月).
在BRCA突变患者中,BRCA1和BRCA2之间没有观察到显著的结果差异,尽管BRCA2BC患者倾向于更长的iDFS和OS.
降低风险的手术,包括逆侧预防性乳房切除和沙卵巢切除,被确定为侵袭性疾病和死亡的负面预测因素.

结论:

葡萄牙BC患者的BRCA PV阳性与复发和死亡风险增加有关.
降低风险的乳房切除术和沙卵巢切除术显示出与减少复发发病率和改善中位数iDFS和OS的显著关联.

关键词:

这就是BRCA1的原因.这就是BRCA2的原因.乳腺癌乳腺癌乳腺癌遗传性乳腺癌是一种遗传性乳腺癌.预后预后预后降低风险的手术.

更多相关视频

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

相关概念视频

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...